Optimizing heart failure treatment following cardiac resynchronization therapy.
Anders JorsalKasper PrydsJohn J V McMurrayHenrik WiggersAnders SommerJens Cosedis NielsenRoni Ranghøj NielsenPublished in: Clinical research in cardiology : official journal of the German Cardiac Society (2019)
In the present study, 38% of those who remained symptomatic 6 months after CRT implantation were eligible for optimization of medical therapy with sacubitril/valsartan, ivabradine, or both. Patients with CRT may benefit from systematic follow-up including evaluation of medical treatment.